The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
Authors:
- Robert E. KalbRKRobert E. Kalb
- Andrew BlauveltABAndrew Blauvelt
- Michael P. HeffernanMHMichael P. Heffernan
- Howard L. SofenHSHoward L. Sofen
- Laura Korb FerrisLFLaura Korb Ferris
- Francisco A. KerdelFKFrancisco A. Kerdel
- Stephen CalabroSCStephen Calabro
- Jim WangJWJim Wang
- Urs KerkmannUKUrs Kerkmann
- Marc ChevrierMCMarc Chevrier
- 1 October 2012
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 67 (4) , 642-650
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Circulating Th17, Th22, and Th1 Cells Are Increased in PsoriasisJournal of Investigative Dermatology, 2010
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- The IL-23/Th17 Axis in the Immunopathogenesis of PsoriasisJournal of Investigative Dermatology, 2009
- Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyAnnals of the Rheumatic Diseases, 2007
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJournal of the American Academy of Dermatology, 2007
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialThe Lancet, 2005
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make senseAnnals of the Rheumatic Diseases, 2003
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003